Sanofi-Synthelabo (SASY.PA: Quote, Profile, Research) and its bankers are working around the clock to get the French drug firm’s 48 billion euro ($61.08 billion) offer for Aventis (AVEP.PA: Quote, Profile, Research) to shareholders as early as this week, sources close to the situation said on Monday.
